Flight path 06 // 7 missions // 5h 14m
From wet lab to term sheet: what drugs really cost, which techbio myths to retire, and the people funding molecules.
Imran Haque — SVP, AI and Digital Sciences, Recursion
Despite $billions of investment, there are still no AI-discovered drugs on the market. Recursion's Imran Haque on why AI drug discovery is so tricky.
Meri Beckwith — Co-founder & CEO, Lindus Health
Drug discovery is becoming more expensive and producing less results than ever before (Eroom's Law). Meri Beckwith is building the anti-CRO: Lindus Health.
Charles Fisher — CEO, Unlearn.ai
Using digital twins to run faster clinical trials with fewer patients — through a biophysics lens.
Guillermo Vela — CEO & Co-Founder, NeuScience
Why it doesn't take $2.5bn to develop a drug and why AI won't make drug discovery faster, better or cheaper.
Jason Foster — CEO, Ori Biotech
Jason Foster is the CEO of Ori Biotech, a cell and gene therapy company that's raised $139M in funding, and an active angel investor.
Niklas Rindtorff — Physician-Scientist; Founder, LabDAO; Core Member, VitaDAO
How DAOs can be used in healthcare — from enabling rare disease research to fixing science's publishing problems.
Stephen Reeders — Founder, MVM Partners
Moving from medicine and science into venture capital, and excelling at all three.